Navigation Links
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Date:9/21/2007

val falls to approximately 15%.(4)

Non-Small Cell Lung Cancer is the most common type of Lung Cancer, making up nearly 80% of all cases. This type of Lung Cancer grows and spreads more slowly than small cell lung cancer. Non-small cell lung cancer is divided into three different subcategories. Squamous cell carcinoma originates in the thin, flat cells that line the passages of the respiratory tract. Adenocarcinoma begins in the cells that form the lining of the lungs. Large cell carcinomas make up a group of cancers that look large and abnormal under a microscope.

About vandetanib (ZACTIMA)

Vandetanib is being studied as a multitargeted compound, directed to the inhibition of key cell signaling pathways involved in tumor growth and spread. Tumor cells are targeted through inhibition of epidermal growth factor receptor (EGFR) and REarranged during Transfection (RET) tyrosine kinases, while tumor blood supply is targeted through inhibition of vascular endothelial growth factor receptor (VEGFR) tyrosine kinase. RET tyrosine kinase activity is an important growth driver in certain lung tumors.

Other studies currently recruiting within the NSCLC Phase III clinical development program are:

-- ZEAL (ZACTIMA Efficacy (or Evaluation) with Alimta in Lung cancer)

-- ZEN (ZACTIMA efficacy in EGFR Failures in Non-small cell lung cancer)

-- ZEST (ZACTIMA Efficacy when Studied versus Tarceva)

The primary endpoints for these studies are PFS and OS.

ZACTIMA(TM) is a trademark of the AstraZeneca group of companies.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncolo
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. Newly Published Study Reveals Femara Improves Chances for Harder to Treat Early Breast Cancer Relapse in Postmenopausal Women
6. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
7. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
8. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
9. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
10. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
11. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SPRING, Md. , Aug. 29, 2014  United ... that the U.S. District Court for the District of ... its favor in the company,s case against Sandoz, Inc. ... Judge Peter Sheridan ruled that U.S. Patent ... Inc., and enjoined Sandoz from marketing its generic product ...
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 2014  Unilife Corporation ("Unilife" or "Company") (NASDAQ: ... intends to release its financial results for the fiscal ... after market trading ends on Tuesday, September 9, 2014. ... for 4:30 p.m. U.S. EDT on Tuesday, September 9, ... review the Company,s financial results, commercial partnerships, and future ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2
... certain mutations enable specific cells in the,retina to ... suggests deliberate,genetic manipulations might coax an injured brain ... Investigators at St.,Jude Children,s Research Hospital have ... cancer retinoblastoma, disproving a long-standing principle of,nerve growth ...
... Oct. 18 CEL-SCI CORPORATION,(Amex: CVM ) ... is a featured presenter at the International Society ... Mr. Kersten will present on the "New Realities ... p.m. (Eastern Daylight,Time). In April 2007, CEL-SCI ...
Cached Medicine Technology:St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 2St. Jude Identifies the Specific Cell That Causes Eye Cancer, Disproving Long-Held Theory 3CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase 2
(Date:8/29/2014)... San Francisco, CA (PRWEB) August 30, 2014 ... the 10 best web conference providers in the online ... Amongst the list were global leaders Webex, GotoMeeting and ... in the industry users have to determine which provider ... Essentially, web conference businesses search for compelling consumer ...
(Date:8/29/2014)... 2014 Honey Gifts, premium Vancouver adult ... now be selling purse-sized adult toys and erotic products. ... they can be carried in a woman’s purse with ... range at Honey Gifts is also leak-free and will ... rechargeable batteries are common characteristics of Honey Gifts’ portable ...
(Date:8/29/2014)... 29, 2014 Sansego is ... an interactive online community, and a range of personalized ... all the way to professional athletes. Crowie has brought ... been with him throughout the majority of his triathlon ... in the triathlon public. , Sansego provides the following:, ...
(Date:8/29/2014)... Work is the recipient of a ... Drug Abuse (NIDA) at the National Institutes of Health (NIH) ... use. Additionally, the grant provides resources to create the infrastructure ... use has increased steadily since 2007 according to NIDA, as ... and more available opioid. , A primary project at ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Ethane Web ... recently launched a new service named HTML web design. ... based service. Before tailoring the service, Ethane Web Technologies ... other companies. The company has done its best efforts ... and able to deliver outstanding results to clients. ...
Breaking Medicine News(10 mins):Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Honey Gifts Now Provides Purse Sized Adult Toys in Vancouver 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3Health News:$1.25 million NIH grant to aid research on impact of heroin use 2Health News:Ethane Web Technologies Launches a New Web Design Service 2
... ... DSPanel today announced the availability of their latest ... DSPanel announced the availability of DSPanel Performance Canvas 2.2 with Planning, ... designed to be used as an accompaniment to Sharepoint 2010 and ...
... ... 140-2 Level Certification , ... (PRWEB) May 26, 2010 -- bTrade announced today that the company’s Managed ... Transfer solutions have received the Federal Information Processing Standards (FIPS) 140-2 (Level 1) validation, ...
... ... special section dedicated to prescription sunglasses , ... New Jersey (PRWEB) May 26, 2010 -- With summer quickly ... in selling prescription glasses has been selling prescription sunglasses since ...
... ... take over as President of the company effective July 1st, 2010. , ... Waterloo, IA (Vocus) May 26, 2010 -- John Spragle recently announced ... VGM Insurance,s plan for my successor. Effective June 1, 2010, Tom Jones will be joining VGM ...
... ... and Curcumin have demonstrated anti-tumor properties and may serve as important therapeutic agents in ... anti-cancer chemicals has been the focus of US based Biomedical Company, Millennium Bioceutics with ... ...
... used a magnetic resonance imaging (MRI) technique called continuous ... patterns in schizophrenic patients quickly and without using radiation ... edition and July printed issue of the journal ... technique that can help reduce the cost and complexity ...
Cached Medicine News:Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 2Health News:DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It 3Health News:bTrade Earns Stringent Government Data Security Certification 2Health News:bTrade Earns Stringent Government Data Security Certification 3Health News:GlassesUSA.com Launches Section for Prescription Sunglasses 2Health News:VGM Insurance President Passes the Baton 2Health News:Natural Chemicals Act As Cancer Killers 2Health News:Blood flows differently through the brains of schizophrenic patients 2
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The upper body blanket covers the upper torso, arms, neck, and head of the patient....
The Electri-Cool® II is the premier choice when it comes to localized cold therapy systems. system offers the widest variety of application-specific pads and wraps, for your convenience....
Complete Cataract Competence , OPMI VISU 140 is compact, good and economical. It's everything a cataract specialist needs today....
Medicine Products: